Clovis Oncology, Inc. (CLVS) Set to Announce Earnings on Wednesday
Clovis Oncology, Inc. (NASDAQ:CLVS) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 1st. Analysts expect Clovis Oncology to post earnings of ($1.18) per share for the quarter.
Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. During the same period last year, the firm earned ($2.07) earnings per share. The company’s revenue was down 32.5% compared to the same quarter last year. On average, analysts expect Clovis Oncology to post $-7.43 EPS for the current fiscal year and $-2.48 EPS for the next fiscal year.
Clovis Oncology, Inc. (NASDAQ:CLVS) opened at 75.68 on Wednesday. Clovis Oncology, Inc. has a 52 week low of $25.81 and a 52 week high of $99.45. The company has a 50-day moving average of $77.56 and a 200 day moving average of $72.00. The firm’s market cap is $3.70 billion.
CLVS has been the subject of several analyst reports. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a report on Tuesday, October 17th. Cann reissued a “hold” rating on shares of Clovis Oncology in a research note on Monday, July 31st. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, October 10th. Bank of America Corporation reissued a “buy” rating on shares of Clovis Oncology in a research note on Thursday, August 3rd. Finally, J P Morgan Chase & Co reissued an “overweight” rating on shares of Clovis Oncology in a research note on Tuesday, August 1st. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $87.56.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $69.50, for a total transaction of $208,500.00. Following the completion of the sale, the insider now directly owns 191,583 shares of the company’s stock, valued at approximately $13,315,018.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James C. Blair sold 18,450 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $78.61, for a total value of $1,450,354.50. Following the sale, the director now directly owns 2,185 shares of the company’s stock, valued at $171,762.85. The disclosure for this sale can be found here. Insiders have sold a total of 27,450 shares of company stock valued at $2,122,625 over the last ninety days. Company insiders own 12.50% of the company’s stock.
WARNING: “Clovis Oncology, Inc. (CLVS) Set to Announce Earnings on Wednesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/25/clovis-oncology-inc-clvs-set-to-announce-earnings-on-wednesday.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.